The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole CB<sub>2</sub> Agonist for the Treatment of Chronic Pain
作者:Gerard M. P. Giblin、Andrew Billinton、Michael Briggs、Andrew J. Brown、Iain P. Chessell、Nick M. Clayton、Andrew J. Eatherton、Paul Goldsmith、Carl Haslam、Matthew R. Johnson、William L. Mitchell、Alan Naylor、Alcide Perboni、Brian P. Slingsby、Alex W. Wilson
DOI:10.1021/jm9009857
日期:2009.10.8
We report the synthesis and SAR of a series of novel azaindole CB2 agonists. 6-Azaindole 18 showed activity in an acute pain model but was inactive in a chronic model. 18 is a Pgp substrate with low brain penetration. The template was redesigned, and the resulting 5-azaindole 36 was a potent CB2 agonist with high CNS penetration. This compound was efficacious in the acute model and the chronic joint pain model.